UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 27, 2017
 
YIELD10 BIOSCIENCE, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
DELAWARE
(State or Other Jurisdiction of Incorporation)
 
001-33133
 
04-3158289
(Commission File Number)
 
(IRS Employer Identification No.)
 
19 Presidential Way, Woburn, Massachusetts
 
01801
(Address of Principal Executive Offices)
 
(Zip Code)
 
(617) 583-1700
(Registrant’s Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   o









Item 8.01. Other Events
 
On June 27, 2017, Yield10 Bioscience, Inc., a Delaware corporation (the “Company”), issued a press release announcing that the Company’s novel C4001 trait (a global regulatory gene or transcription factor) has been shown to significantly increase plant biomass yield in switchgrass. The Company plans to evaluate C4001-like traits in forage crops and major commercial crops including corn and rice. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits
(d)
Exhibits.
 
 
Exhibit No.
Description
 
 
Press Release dated June 27, 2017.
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
 
 
 
 
 
YIELD10 BIOSCIENCE, INC.
 
 
 
Date: June 27, 2017
By:
/s/ Charles B. Haaser
 
 
Charles B. Haaser
 
 
Chief Accounting Officer



Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Yield10 Bioscience Charts.
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Yield10 Bioscience Charts.